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Abstract Hepatocellular carcinoma (HCC) is one of the
most common and rapidly fatal malignancies world-
wide with a multifactorial, multistep, complex process
and poor prognosis. Its early diagnosis and metastasis
monitoring are of the utmost importance. Hepatoma
tissues synthesize various tumor-related proteins, genes,
enzymes, microRNA, etc. and then secrete into the
blood. Detections of circulating biomarkers are useful
to find tumor at an early stage or monitor metastasis
after postoperative treatment. This paper summarizes
recent studies of specific biomarkers at early diagnosis
or in monitoring metastasis or postoperative recurrence
of HCC.
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Abbreviations
GPC-3 Glypican-3
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
HCV Hepatitis C virus
HS-AFP HCC-specific AFP
HS-GGT HCC-specific gamma-glutamyltransferase
HSP Heat shock protein
IGF Insulin-like growth factor
miRNA MicroRNA
PBMC Peripheral blood mononuclear cell
PCR Polymerase chain reaction
TGF Transforming growth factor
Introduction
Hepatocellular carcinoma (HCC) is the third deadliest and
fifth most common cancer worldwide [1, 2]. HCC ranks the
second in China among all malignancies, and its mortality is
almost equal to its morbidity. Carcinogenesis of HCC is a
multifactor, multistep, complex process, which is associated
with a background of chronic liver diseases or persistent
infection of hepatitis B virus (HBV) or hepatitis C virus
(HCV), along with alcohol and aflatoxin B1 intake which
are widely recognized etiological agents in HCC [3, 4].
However, the underlying mechanisms that lead to malignant
transformation of infected cells remain unclear. Most of HCC
patients died quickly because of the rapid tumor progression,
and hepatic resection or transplantation is the only potential
curative treatment for HCC patients [5]. Although the mortal-
ity of HCC has significantly decreased with the development
of surgical techniques, about 60~100 % of the patients suf-
fered from HCC recurrence ultimately even after curative
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resection, and it has become the most important factor that
limits the long-term survival of HCC patients [6].
The most urgent needs are to find sensitive markers for
early diagnosis or monitor postoperative recurrence and to
give adequate treatment for HCC. It has many characteristics,
such as fast infiltrating growth, metastasis in early stage, high-
grade malignancy, and poorly therapeutic efficacy, with the
prognosis that is poor and early detection that is of the utmost
importance [7]. Although serum alpha-fetoprotein (AFP) level
is a useful tumor marker for the detection and monitoring of
HCC, the false negative rate with AFP level alone may be as
high as 40 % for patients with early stage HCC. Even in
patients with advanced HCC, the AFP levels may remain
normal in 15~30 % of the patients [8]. New specific markers
[9, 10], such as circulating HCC-specific gamma-
glutamyltransferase (HS-GGT) [5], HCC-specific AFP (HS-
AFP or AFP-L3) [11, 12], microRNA (miRNA) [13],
glypican-3 (GPC-3) [14], and Golgi glycoprotein 73 [15,
16], have been developed to improve the sensitivity, specific-
ity, early detection, and prediction of prognosis. However, the
overall results have been unsatisfactory [17, 18]. The present
article summarizes recent studies of the specific molecular
markers in early diagnosis and monitoring metastasis or post-
operative recurrence of HCC.
Hepatoma-specific AFP and AFP-messenger RNA
AFP, a 70-kD glycoprotein synthesized from the fetal yolk
sac, liver, and intestines, has a half-life of 5~7 days. Total
serum AFP level is a prognostic indicator of the response and
survival of germ cell tumors [19]. However, when an AFP
level is slightly elevated, it may be falsely elevated owing to
nonneoplastic liver disease [20]. Although total AFP is a
useful serological marker for HCC diagnosis, the false nega-
tive rate or false positive rate with AFP level alone may be as
high as 40 %, especially for its early diagnosis or the finding
of small size HCC (<2 cm). It is sometimes very difficult to
make the distinction between tumors and falsely elevated AFP
levels because of benign liver diseases (Fig. 1a, b) [21].
Recently, the separation of a HS-AFP subfraction has been
reported to be superior to total AFP level in both sensitivity
and specificity in differentiating between benign and malig-
nant liver diseases [22].
Total AFP can be divided into three different glycoforms
(Fig. 1c), AFP-L1, AFP-L2, and AFP-L3 (Fig. 1d), according
to their binding capacity for lens culinaris agglutinin (LCA) or
their isoelectric point difference. HS-AFP, as the LCA-bound
fraction, is the major glycoform of AFP in the sera of HCC
patients. Early diagnosis is very important for HCC. With a
HS-AFP of more than 15 %, the levels of serum AFP and HS-
AFP inHCCwere significantly higher than those in other liver
diseases [23]. Although total AFP level in liver cirrhosis was
significantly higher than that in chronic hepatitis or normal
control, no significant relationship was found between the
percentage of HS-AFP and total AFP level, HBsAg-positive
or HBsAg-negative status, tumor size, or number. However,
there was a relationship with HCC differentiation, metastasis,
and relapse, suggesting that the percentage of HS-AFPmay be
a more specific marker than total AFP for early diagnosis and
recurrence of HCC [24–26].
The genetic markers or tumor-specific protein can monitor
carcinogenesis of hepatocytes and can diagnose HCC at an
early stage of HCC development. Angiogenesis is necessary
for solid tumors larger than 1×1 mm; otherwise, the tumor
remains dormant and does not metastasize [25]. As soon as it
enters the angiogenesis stage, metastasis potency is exhibited.
AFP messenger RNA (mRNA) from peripheral blood mono-
nuclear cells (PBMCs) by reverse transcription-polymerase
chain reaction (PCR) has been most extensively studied in
recent years (Fig. 2). Using the appropriate single tumor
marker or combination of other markers may improve the
effectiveness in screening HCC patients [27, 28]. If HCC-
specific mRNAs are detected in the circulating blood, it is
possible to infer the presence of circulating, presumably ma-
lignant liver cells and to predict the likelihood of hematoge-
nous metastasis. By now, many clinical, tumor genetic and
molecular biological markers have been used to diagnose
HCC or to predict HCC recurrence, but it is a frequently
encountered situation that different conclusions were drawn
from different researches concerning the value of the same
predictor. As circulating cancer cells are an important source
for HCC metastasis, the biomarkers that indicate the malig-
nant cell existence may be a useful predictor for HCC extra-
hepatic metastasis [29, 30].
HS-GGT isoforms
GGT (Enzyme Commission number 2.3.2.2) is a membrane-
bound enzyme that catalyzes the degradation of glutathione and
other gamma-glutamyl compounds by hydrolysis of the
gamma-glutamyl moiety or by its transfer to a suitable acceptor
[31, 32]. This enzyme exhibits a tissue-specific expression that
is modified under various physiologic and pathologic condi-
tions, such as development and carcinogenesis. It is highest in
the embryo livers and decreases rapidly to the lowest levels
after birth, and it is a widely distributed enzyme that has been
extensively studied in relation to hepatocarcinogenesis. GGT is
a heterodimeric glycoprotein [33, 34], and its total activity in
patients with liver diseases and extrahepatic tumors was abnor-
mally increased. Several studies have demonstrated that these
increases are often associated with structural changes of its
sugar chains, as evidenced by a variation in the pattern of serum
GGT isoforms, suggesting that evaluations of GGT multiple
forms might improve the specificity of GGT measurement and
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that there might be a correlation between specific patterns and
different disease states [35, 36].
GGT is re-expressed during the HCC development and can
be divided into several subfractions according to different
electrophoresis mobility. HS-GGT bands (including I′, II, and
II′) in sera of HCC patients can be separated by a vertical slab
electrophoresis assay of polyacrylamide stage gradient gel and
have been used in HCC diagnosis [37, 38]. Hepatic GGTwith
alteration of the gene methylation status is re-expressed during
the HCC development. HS-GGT is a part of total GGTactivity
that can only be found in sera of HCC patients and has been
confirmed as a useful specific molecular marker, and its anal-
ysis may improve the specificity and sensitivity of HCC diag-
nosis. The circulating HS-GGT activity was significantly ele-
vated in the HCC patients with an incidence of 86% at the level
of over 5.5 IU/L and in patients with other liver diseases with
an incidence of <3 % (Fig. 3) [39].
From cancer to noncancerous tissues, an increasing tenden-
cy of total RNA expression was found [40, 41]. The frequen-
cies of the amplified fragment and the hypomethylated M3
site of GGT genes were 100 and 75 % in HCC tissues, 85 and
55 % in paracancerous tissues, and 75 and 50 % in
noncancerous tissues, respectively. An inverse correlation
was found between methylational degrees of GGT genes
and GGT levels. The abnormal alteration of serum HS-GGT
level is a sensitive tumor marker for diagnosis or differentia-
tion of HCC, and its overexpression in HCCmay be related to
the gene hypomethylational status of CCGG sites [39].
According to the greatest HCC dimension, there are two
groups of patients: <5 cm and >5 cm. The diagnostic values of
AFP and HS-GGT levels were 42 % in AFP and 76 % in HS-
GGT for small size HCC and 83 % in AFP and 92 % in HS-
GGT for large size HCC, respectively. The abnormal frequen-
cy in the <5 cm group was significantly higher (P <0.01) in
HS-GGT than that in AFP. A significant correlation was found
between AFP levels and tumor size (P <0.01). According to
AFP levels (<50, 51~499, 500~999, and >1,000 ng/mL), the
frequency of HS-GGTactivity >5.5 IU/mL in HCC was 79.6,
96.4, 88.9, and 86.9 %, respectively. The HS-GGT positive
rate was 79.6 or 89.7 % in the AFP <50 or >50 ng/mL group.
No significant relation was found between AFP level and HS-
GGT activity. However, the positive AFP could be found in
HCC with low HS-GGT levels. A comparative analysis of
HS-GGT and AFP markers for HCC diagnosis is shown in
Table 1. The sensitivity, specificity, positive predictive or
negative predictive value, and accuracy of HS-GGT quantita-
tive analysis in HCC diagnosis were superior to the same
values for AFP marker [39].
Glypican-3 and its gene transcription
GPC-3 is a membrane-anchored heparin sulfate proteoglycan
normally expressed in the fetal liver and placenta, but not in
the normal adult liver [42, 43]. It is an oncofetal antigen that is
a reliable circulating biomarker for HCC and has not been
observed in benign liver lesions by in situ hybridization or
immunohistochemistry [44]. High-grade dysplastic nodules
typically express GPC-3 in a weak and focal fashion, although
the results have not been consistent across different series
Fig. 1 Immunohistochemical
staining of hepatic AFP expression
and molecular features in HCC.
a AFP in HCC tissues (SP, ×400).
b AFP in precancerous tissue (SP,
×400). c AFP isoelectric point (pI)
from different tissues. d The
separation of AFP-L3 by a mini-
column chromatography
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[45]. GPC-3 expression in hepatocarcinogenesis was previ-
ously investigated by rat HCC models, with the brown posi-
tive GPC-3 expression mainly distributed in cytosol, and
membrane, with 100 % in precancerous or cancerous tissues,
and was associated with hepatocyte malignant transformation
that it is an early biomarker for HCC. The expression and
distribution of liver GPC-3 analyzed by immunohistochemistry
with anti-GPC-3 antibody are shown in Fig. 4. The positive
GPC-3 expression showed brown particles and located in
cytosol and cell membrane with only a few in cellular nuclei
with its diffusely staining in cancerous tissues (Fig. 4a) signif-
icantly higher than that in their paracancerous or distal
Fig. 2 Amplification of AFPmessenger RNA (mRNA) from the livers or
PBMCs and the alignment of amplified sequences. a The glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) genome were used as a
control. b The amplification of AFP genomes. Lanes 1 and 2 indicate
positive AFP fragments from HCC tissues; 3 , positive AFP fragments
from paracancerous tissue; 4 , negative result from noncancerous tissue; 5
and 6 , negative result from circulating PBMCs of patients with liver
cirrhosis or chronic hepatitis. c The limitation for AFP mRNA analysis
was 2 ng/L in the detection system. d Alignment of nucleotide sequences
of the amplified fragments of AFP genome in hepatoma or PBMCs from
HCC patients. Origin: the cited sequence of AFP genome; Hepatoma:
hepatoma tissue; PBMCs: blood from HCC patient
Fig. 3 Diagnostic values of circulating HS-GGT activities in sera of
patients with liver diseases or extrahepatic tumors. AH acute hepatitis,
CH chronic hepatitis, LC liver cirrhosis, ET extrahepatic tumor, NC
normal controls
Table 1 Relation between AFP levels and HS-GGT activities
AFP (ng/mL) No. HS-GGT (>5.5 IU/L)
Positive (%) Negative (%)
<50 49 39 (79.6) 10 (20.4)
51~499 28 27 (96.4) 1 (3.6)
500~999 18 16 (88.9) 2 (11.1)
>1,000 61 53 (86.9) 8 (13.1)
Total 156 135 (86.5) 21 (13.5)
HS-GGT hepatoma specific γ-glutamyltransferase, AFP alpha-fetoprotein
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cancerous tissues (Fig. 4b), indicated that the positive GPC-3
was markedly increased with specific expression in HCC con-
firmed by Western blotting (Fig. 4c) [46].
The incidence of GPC-3 expression in HCC group
(80.6 %) was significantly higher than that in paracancerous
or distal cancerous groups (P <0.001), with the paracancerous
group significantly higher than that in the distal cancerous
group (P <0.001). The clinicopathological characteristics
demonstrated that no significant difference was found be-
tween GPC-3 intensity and differentiation degree, age, gender,
tumor number, and AFP levels except that between tumor size
(>3 vs. <3 cm, P <0.05) and HBV infection (Table 2). The
fragment of GPC-3 mRNA in PBMCs and cancerous and
paracancerous tissues can be amplified and confirmed by
sequencing, but not in distal cancerous tissues or PBMCs
from cases with benign liver diseases [43, 47].
The incidence of circulating GPC-3 mRNAwas 70.7 % in
HCC and 2.0 % in cases with benign liver diseases or non-
liver tumors. The significant higher incidence of GPC-3
mRNA was found in HCC patients with I and II vs. III and
IV staging, HBV infection, and small size tumor, especially in
HCC patients with the periportal cancer embolus or the extra-
hepatic metastasis group higher than that the without
periportal cancer embolus or extrahepatic metastasis group
(Table 2) [48, 49]. The quantitative GPC-3 levels showed that
only GPC-3 was overexpressed in HCC (52.8 %) and 1.4 % in
cases with benign liver diseases or 2.0 % in non-liver tumors,
with significant differences between the HCC group and each
of the study groups. The non-GPC-3 expression in sera of
cases with benign liver diseases was detected except of one
case with cirrhosis. There were no false positives among
patients with acute or chronic hepatitis or among healthy
subjects. However, in compared with AFP for HCC diagnosis,
the higher positive result (up to 20.0 %) of AFP could be
found in benign liver diseases, although the AFP positive rate
was higher (70.73 %). According to tumor size, the abnormal
frequency of serum GPC-3 was significantly higher (P <0.01)
in the <3 cm group (80.0 %) than that in the >3 cm group
(41.7 %).
The combining diagnostic values of circulating GPC-3,
GPC-3 mRNA, and AFP levels for HCC are shown in
Table 3. The positive rate in 123 HCC patients was 52.8 %
in serum GPC-3, 70.7 % in positive GPC-3 mRNA from
circulating PBMC, and 70.7 % in AFP. Total positive rates
of circulating GPC-3 and its gene in combination with AFP
could rise up to 94.3 % for HCC diagnosis. The detecting
GPC-3 and GPC-3mRNAwere superior to AFP in sensitivity,
specificity, positive predictive or negative predictive value,
and accuracy for HCC. The detection of circulating GPC-3 or
its gene transcription in HCC specificity was superior to
serum AFP alone, with efficacious in HCC differentiating
diagnosis or monitoring hematogenous metastasis. Both com-
bining applications of GPC-3 and AFP should rise up the
HCC diagnostic sensitivity [50].
Fig. 4 Immunohistochemical
staining and Western blotting
analysis of hepatoma GPC-3
expression. a The GPC-3-positive
cytoplasm in cancerous tissues. b
GPC-3 in positive cancerous or
negative paracancerous tissues (SP,
X 200). c The analysis of liver
GPC-3 expression by Western
blotting. Lanes 1–4 indicate liver
tissues from HCC patients. HCC:
the cancerous tissues; Para-can:
their paracancerous tissues; Dis-
can: their distal cancerous tissues
Tumor Biol. (2014) 35:9–20 13
Transforming growth factor-β1 and its mRNA
Transforming growth factor (TGF)-β is a family of related
proteins that regulate many cellular processes including growth,
differentiation, extracellular matrix formation, and immunosup-
pressant [51]. Every cell in the body, including epithelial, endo-
thelial, hematopoietic, neuronal, and connective tissue cells,
produces TGF-β and has receptors for it. TGF-β1 is one of
TGF-β isoforms (TGF-β1–5) and arrests the cell cycle in the G1
phase, thereof eliciting inhibition of cell proliferation and trig-
gering apoptosis [52, 53]. In normal liver tissues, TGF-β1 is
produced only by nonparenchymal cells (Kupffer's cell, fat
storing cell, and endothelial cell). Previous studies have shown
upregulated expression of TGF-β1 in tumor cells, including
HCC. Though a growth inhibitor, the overexpression of hepatic
TGF-β1 was found in HCC tissues and correlated with carcino-
genesis, progression, and prognosis of HCC [3, 54, 55]. TGF-β1
expression was increased as the HBV-induced disease
progressed from chronic liver diseases to cirrhosis and then to
HCC. In in vitro study, immunohistochemistry and in situ hy-
bridization revealed that normal hepatocytes had not any
TGF-β1 staining [56, 57], but hepatocytes in regenerative and
cirrhotic livers and HCC cells expressed different degrees of
TGF-β1 and its mRNA.
As the longevity of liver cirrhosis and HCC cells was ob-
served compared to normal hepatocytes, it is plausible to pro-
pose that TGF-β1 up-expression in these tumor cells is closely
related to the cell survival, thereof possibly escaping the control
of cell proliferation by TGF-β [58]. The incidence of hepatic
TGF-β1 expression was higher in HCC (83 %) and lower in
their surrounding tissues, and the incidence was 95% in positive
HBV-DNA group and 64 % in negative HBV-DNA one, re-
spectively. TGF-β1 expression is associated with HCC differen-
tiation degree and status of HBVreplication, but neither to tumor
size nor to number. The levels of circulating TGF-β1 and
TGF-β1 mRNA were significantly higher in HCC than those
in any of other patients. Sensitivity or specificity of circulating
TGF-β1 level (>1.2 μg/L) was 90 or 94 % for HCC diagnosis,
but no significant correlation was found between TGF-β1 and
AFP expression or tumor sizes. Combining TGF-β1 and AFP
could raise the positive rate up to 97 %. Both of circulating
TGF-β1 and its mRNA could be used as sensitive biomarkers
for the diagnosis or prognosis of HBV-induced HCC [59, 60].
Insulin-like growth factor-II and its mRNA
Insulin-like growth factor (IGF)-II is a mitogenic polypeptide
closely related to insulin, and its gene has a complex regulation
of transcription, resulting in multiple mRNAs initiated by dif-
ferent promoters [61, 62]. IGF-II is speculated to serve as an
autocrine growth factor in various cancers with increasing IGF-I
receptor, and it is a kind of fetal growth factor, and highly
Table 2 The pathological characteristics of circulating GPC-3 mRNA in
PBMCs from HCC patients
Group No. of cases GPC-3 χ2 P
Positive Negative
Sex
Male 103 74 29 0.379 0.538
Female 20 13 7
Age
≥60 years 56 39 17 0.059 0.808
<60 years 67 48 19
TNM staging
I and II 47 39 8 5.551 0.019
III and IV 76 48 28
Tumor size
≥3.0 cm 98 65 33 4.520 0.034
<3.0 cm 25 22 3
AFP (ng/mL)
≥400 52 36 16 0.098 0.754
<400 71 51 20
HBsAg
Positive 89 79 10 50.571 <0.001
Negative 34 8 26
Tumor number
Single 58 40 18 0.165 0.685
Multiple 65 47 18
Child-Pugh
A 60 40 20 1.005 0.605
B 45 34 11
C 18 13 5
Periportal cancer embolus
With 44 44 0 28.347 <0.001
Without 79 43 36
Extrahepatic metastasis
With 65 65 0 57.019 <0.001
Without 58 22 36
Table 3 Combining diagnostic values of circulating GPC-3, GPC-3
mRNA, and AFP levels for HCC
GPC-3 GPC-3 mRNA AFPa Total
Sensitivity (%) 52.8 70.7 70.7 94.3
Specificity (%) 98.8 99.8 86.2 85.8
Diagnostic accuracy (%) 83.5 89.4 81.0 88.6
Positive predictive value (%) 95.6 96.7 71.9 76.8
Negative predictive value (%) 80.7 87.1 85.5 96.8
a AFP level was more than 20 ng/mL
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abnormality in hepatocarcinogenesis and re-expression of its
gene has recently been described in HCC [63, 64]. HCC is
generally considered to be a hypervascular tumor. Although
hepatic arterial embolization is widely used as an effective
treatment of HCC on the basis of HCC hypervascularization,
IGF-II may play an important role in the development of HCC
neovascularization, because IGF-II substantially increases vas-
cular endothelial growth factor (VEGF) at mRNA or protein
levels in a time-dependent manner [63, 65].
HCC is a common malignant disease with poor prognosis.
Underlying molecular mechanism provides a potential to de-
velop new therapeutic target, which is very urgent. The induc-
tion of VEGF by IGF-II was additively increased by hypoxia,
and IGF-II may be a hypoxia-inducible angiogenic factor in
HCC and stimulates the growth of HCC cells in vitro. Most of
cirrhotic and HCC tissues express IGF-II (Fig. 5). However,
little is known of its circulating IGF-II gene in HCC [66, 67].
The positive frequencies of IGF-II mRNA were 100 % in
HCC, half in paracancerous or none in noncancerous tissues,
respectively. The circulating free IGF-II levels were signifi-
cantly higher in HCC than those in chronic liver disease. IGF-
II abnormally expressed during HCC development [65].
Recent studies revealed that circulating IGF-II mRNA corre-
lated well with the presence of extrahepatic metastases in
HCC patient. The role of IGF-II in HCC cell proliferation
and antiapoptosis is well established. Specific and efficient
miRNA inhibited the IGF-II expression for exploring the
effect of IGF-II inhibition on the growth, as well as
metastasis-related biological behaviors of HCC [68, 69].
Genetic alterations of telomerase
Telomerase, an RNA-dependent DNA polymerase, can main-
tain the telomeric length by acting as a reverse transcriptase. In
humans, tumor cells escape programmed cell senescence
through reactivation of telomerase [70, 71]. These immortal-
ized cells can compensate for telomeric shortening at each cell
division, leading to progressive neoplastic evolution.
Telomerase re-expression was found in 85 % of malignant
tumors [72, 73]. Maybe HBV infection is merely a carcino-
genic factor and is not related to the growth, infiltration, and
metastasis of HCC. It is increasingly clear that oncogenesis is
driven by telomerase activation, a ribonucleoprotein complex
that adds telomeric repeats (hexa-nucleotide 5′-TTAGGG-3′)
to the ends of replicating chromosomes. Telomerase is a
ribonucleoprotein composed of an essential RNA and a few
proteins and is expressed in embryonic cell and in adult male
germ line cells but undetected in normal somatic cells except
proliferative cells of renewable tissues [74].
The expression of telomerase is important to cell prolifer-
ation, senescence, immortalization, and carcinogenesis. The
hepatoma model displayed the dynamic expression of hepatic
telomerase during HCC development and up to its highest
Fig. 5 Expressions of liver IGF-II
or its gene transcription and
diagnostic value of circulating IGF-
II. a IGF-II in distal cancerous
tissues. b IGF-II in cancerous
tissues. c IGF-II mRNA in HCC,
paracancerous, and distal
cancerous tissues. d The receiver
operating characteristic curves of
serum IGF-II in HCC with the area
0.823 for AFP and 0.771 for IGF-II
Tumor Biol. (2014) 35:9–20 15
peak at the stage of HCC formation. Its activities were con-
sistent with liver total RNA levels at the stages of degenera-
tion, precancerosis, and cancerization of hepatocytes. The
telomerase levels in HCC tissues were also significantly
higher than those in their adjacent noncancerous tissues, but
liver total RNA levels were lower in the former than those in
the latter. Although the circulating telomerase of HCC patients
was abnormally expressed among cases with chronic liver
diseases, its activity was a nonspecific marker for HCC diag-
nosis, because the incidence was lower in control or in chronic
liver diseases and 83 % in HCC when absorbance was >0.2,
respectively. If the value was >0.6, the incidence was 63 % in
HCC and none in any of the others except for two cases with
liver cirrhosis [46], with AFP detection increasing the accura-
cy (93 %) for HCC diagnosis, suggesting that telomerase
expression was associated with HCC development, and its
abnormality could be a useful marker for diagnosis and prog-
nosis of HCC [75, 76].
Heat shock protein
Heat shock protein (HSP) is a highly conserved protein pro-
duced under the perturbation or stressors of many physical
and chemical factors. It participates in the complex formation
of many proteins, contributes to the folding and extension of
proteins as well as the assembly of polycomplex, functions in
protein transport between cell organelles, and regulates the
target proteins other than changes of their construction [77,
78]. Thus, it is defined as a molecular chaperone. HSPs are
ubiquitous molecules induced in cells exposed to various
stress conditions, including carcinogenesis. Previous studies
have shown an upregulated expression of gp96 in tumor cells
as an apoptosis inhibitor, abnormal HSP correlated with car-
cinogenesis, progression, and prognosis of HCC. HSP gp96
(or GRP94) as a putative high-density lipoprotein-binding
protein in the liver and a member of the HSP90 family
(HSP83, HSP84, HSP87, HSP90 gp96, etc.) binds the reper-
toires of peptides, thus eliciting peptide-specific T cell im-
mune responses. It predominantly locates inside the endoplas-
mic reticulum with some cell surface expression in certain
cancerous cells. Enhancement of intracellular HSP is closely
related to the formation and development of HCC [79] and a
vital marker indicating the progression and aggravation of
HCC [7, 80].
HSP90 is required for the activity of HBV reverse tran-
scriptase. The gp96 expression is increased as the HBV-
induced disease progresses from chronic hepatitis to cirrhosis
and then to HCC. The longevity of cirrhotic and HCC cells
compared to normal hepatocytes is plausible to propose that
increased gp96 expression in these tumor cells is closely
related to the cell survival, thereof possibly by preventing cell
apoptosis. The gp96 was strongly expressed in HCC (73.3 %)
and was weakly expressed in noncancerous tissues, correlated
with the degree of tumor differentiation or size, but not with
tumor number. The data of immunohistochemical analysis
showed that 90 % of HCC patients with positive HBV-DNA
were strongly expressed for gp96, whereas only 46 % of the
patients with HBV-DNA-negative were positive for gp96
[81].
HSP70 and HSP27 among HSPs are of special relevance in
cancer, inhibiting apoptosis and frequently staining in the
cytoplasm and nuclei of tumor cells, but not in nonneoplastic
hepatocytes. Immunoreactivity of HSP70 or HSP27 was ob-
served in 56.3 and 61.9 % of HCC; the former was correlated
with high Ki-67-labeling indices (LIs), large tumor size, pres-
ence of portal vein invasion, and high tumor stage, and the
latter was significantly related to the subgroup of HBV-
associated HCCs, but not to others. Both HSP70 and HSP27
immunoreactivities showed no relation to Apotag LIs or p53
immunoreactivity. Expressions of HSP70 and HSP27 might
play an important role in hepatocarcinogenesis, and HSP70, in
particular, was closely related to the pathological parameters
associated with HCC progression [82, 83].
Circulating microRNAs
miRNAs are small noncoding RNAs that function as endog-
enous silencers of numerous target genes [84, 85]. Hundreds
of miRNAs have been identified in human genome. miRNAs
are expressed in a tissue-specific manner and play important
roles in cell proliferation, apoptosis, and differentiation of
HCC. Aberrant expression of miRNAs may also contribute
to the development and progression of HCC, and miRNAs
play roles as tumor suppressors or oncogenes. miR-122 , let-7
family, and miR-101 are downregulated, and they are poten-
tial tumor suppressors of HCC. miR-221 and miR-222 are
upregulated in HCC and may act as oncogenic miRNAs in
hepatocarcinogenesis. miRNA expression profiling may be a
powerful clinical tool for the diagnosis and regulation of
miRNA expression which could be a novel therapeutic strat-
egy for HCC [86, 87].
Many studies have shown that miRNAs play a crucial role
in driving organ and tissue differentiation during embryogen-
esis and in the fine-tuning of fundamental biological process-
es. The role of miRNAs in HCC is analyzed for exploring the
possible mechanisms by which they contribute to this neo-
plasm. Moreover, the possible role of circulating miRNAs as
biomarkers, a field that needs urgent improvement in the
clinical surveillance of HCC, and the fascinating possibility
of using them as therapeutic targets or drugs themselves [88]
were also analyzed. Several miRNAs are involved in HBVor
HCV replication and virus-induced changes, whereas others
participate in multiple intracellular signaling pathways that
modulate apoptosis, cell cycle checkpoints, and growth
16 Tumor Biol. (2014) 35:9–20
factor-stimulated responses. When disturbed, these pathways
appear to result in malignant transformation and, ultimately,
HCC development. It could also serve as indicators with
respect to drug efficacy and be prognostic in HCC. Such
biomarkers would assist in the stratification of HCC and help
in direct personalized therapy [89].
Perspectives
Hepatoma has exhibited numerous genetic abnormalities as
well as epigenetic alterations including modulation of DNA
methylation [90, 91]. Molecular factors are involved in the
process of HCC development and metastasis [92, 93]. Several
laboratories have implicated constitutive activation of miRNA
as one of the early key events involving in liver neoplastic
progression [94, 95]. Further studies will permit us to analyze
the mechanism of hepatocarcinogenesis and to pay attention
to these areas [96]. However, the combination of pathological
features and some biomarkers with high sensitivity and spec-
ificity for early diagnosis and metastasis of HCC seems to be
more practical up to present.
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